Houston innovator receives $5M to establish new center that explores crystallization process

crystal clear initiative

With this new grant, UH has a new center for researching bioactive materials crystallization. Photo via UH.edu

A new hub at the University of Houston is being established with a crystal-clear mission — and fresh funding.

Thanks to funding from Houston-based organization The Welch Foundation, the University of Houston will be home to the Welch Center for Advanced Bioactive Materials Crystallization. The nonprofit doled out its inaugural $5 million Catalyst for Discovery Program Grant to the new initiative led by Jeffrey Rimer, Abraham E. Dukler Professor of Chemical Engineering, who is known internationally for his work with crystals that help treat malaria and kidney stones.

“Knowledge gaps in the nascent and rapidly developing field of nonclassical crystallization present a wide range of obstacles to design crystalline materials for applications that benefit humankind, spanning from medicine to energy and the environment,” says Rimer in a news release. “Success calls for a paradigm shift in the understanding of crystal nucleation mechanisms and structure selection that will be addressed in this center.”

The Welch Foundation, which was founded in 1954, has granted over $1.1 billion to scientists in Texas. This new grant program targets researchers focused on fundamental chemical solutions. Earlier this year, the organization announced nearly $28 million in grants to Texas institutions.

"Support from the Welch Foundation has led to important advances in the field of chemistry, not only within Texas, but also throughout the United States and the world as a whole,” says Randall Lee, Cullen Distinguished University Chair and professor of chemistry, in the release. “These advances extend beyond scientific discoveries and into the realm of education, where support from the Welch Foundation has played a significant role in building the technological workforce needed to solve ongoing and emerging problems in energy and health care.”

Rimer and Lee are joined by the following researchers on the newly announced center's team:

  • Peter Vekilov, Moores Professor, chemical and biomolecular engineering
  • Alamgir Karim, Dow Chair and Welch Foundation Professor, chemical and biomolecular engineering;
  • Jeremy Palmer, Ernest J. and Barbara M. Henley Associate Professor, chemical and biomolecular engineering
  • Gül Zerze, chemical and biomolecular engineering
  • Francisco Robles Hernandez, professor of engineering technology.

The University of Houston also received another grant from the Welch Foundation. Megan Robertson, UH professor of chemical engineering, received $4 million$4 million for her work with developing chemical processes to transform plastic waste into useful materials.

“For the University of Houston to be recognized with two highly-competitive Welch Foundation Catalyst Grants underscores the exceptional talent and dedication of our researchers and their commitment to making meaningful contributions to society through discovery,” Diane Chase, UH senior vice president for academic affairs and provost, says in the release.

From Your Site Articles
Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Real estate giant taps downtown Houston tower for new smart building tech

hi, tech

Houston-based real estate giant Hines is rolling out a new smart building platform with the goal of better serving workers and workplaces at its buildings across the country, including one building in Houston that's aiming to be an office building of the future.

From the employee perspective, the new Hines app will allow employees and employers to book spaces within buildings, order food from on-site cafes and restaurants, book on-site fitness classes and access the building via their smartphone or smartwatch. For employers and tenants, the app will help them gain insights into building performance, occupancy data, ESG targets and employee satisfaction, according to a statement from Hines.

“We’re committed to a people-centric experience and this investment takes that commitment to the next level,” Ilene Goldfine, chief digital strategy officer at Hines, says in a statement. “The traditional systems were managed building by building and made it difficult or impossible to track performance across a portfolio. This new digital ecosystem, which unites back-end technology with front-end experiences, will deliver long-term cost savings to our investors and clients.

"Our clients will also be able to track employee satisfaction, make informed decisions about their space needs and ensure they’re monitoring their carbon targets,” Goldfine continues.

The new digital platform will be launched at eight Hines buildings across five cities, including 717 Texas Ave., a 33-story Class A office tower in Downtown Houston.

The other buildings where Hines will roll out the app include:

  • Salesforce Tower in Chicago
  • 1144 15th Street in Denver
  • The Kearns Building in Salt Lake City
  • CIBC Square in Toronto
  • T3 Bayside in Toronto
  • Two buildings at T3 Sterling Road in Toronto

The company plans to add more locations across its global portfolio.

Hines' opened its first location of The Square coworking space at 717 Texas Ave. in 2020 as part of its coworking concept Hines². The company, in collaboration with Montreal-based Ivanhoé Cambridge, opened a second Houston location of The Square recently and has a coworking space in The Kearns Building in Salt Lake City where it will roll out the new app.

Earlier this year, Hines also launched a sustainability-focused business unit, known as EXP by Hines. The unit, led by Hines veteran Doug Holte, aims to address “the disruptive changes in the built environment.”

Houston expert encourages energy industry to bridge its generational divides

guest column

What’s the biggest obstacle between us and net-zero? Is it policy? Technology? Financing? All of these are important, yes, but none of them is what is really holding us back from our energy transition goals.

The biggest obstacle is a lack of open-mindedness and an unwillingness of people across the industry and across generations to work together.

In October of 2022, I was invited to speak at Energy Dialogues’s North American Gas Forum, a conference that brings together executives from across the energy industry. Over the two days of the conference, I was amazed by the forward-thinking conversations we were having on decarbonization, the future of clean energy, emissions reduction, and much more. I returned back to campus at Duke University, energized by these conversations and excited to share them. But rather than seeing the same sense of excitement, I was met with doubt, disbelief, even scorn.

There’s a fundamental distrust between generations in this industry, and it goes both ways. Experienced energy professionals often see the younger generation as irrational idealists who are too politicized to be pragmatic, while the younger generation often paints the older generation as uncaring climate denialists who want nothing to do with clean energy. Neither is true.

Over the past two years since founding Energy Terminal, I’ve met hundreds (maybe thousands) of people all across the energy industry, from CEOs of major energy companies to students just getting started on their career journey. Despite being so different on the surface, their goals are strikingly similar. Almost all can agree on three things: we want to reduce emissions, we want to expand energy access, and we want to do so while encouraging economic prosperity. The perceived barrier between generations in the energy industry is exponentially larger than the actual barrier.

For experienced professionals — take a chance to engage in conversations with young energy leaders. Understand their priorities, listen to their concerns, and find the middle ground. We are a generation passionate about impact and growth, and enabled with the right resources, we can do incredible things. The changing energy world presents unbelievable opportunities for both progress and profit, but without the next generation on board, it will never be sustainable.

For the young energy leaders of the future–listen to the experiences of the leaders that have come before us. Understand the balance between energy that is clean with energy that is secure, reliable, and affordable. We have brilliant ideas and an insatiable appetite for progress, but we won’t do it alone. Every person and every company has a valuable role to play in the energy transition, so consider how we can amplify our strengths rather than attack each other’s weaknesses.

If my co-founder, a climate activist from New York, and myself, the son of an oil and gas family from south Texas, can do it, so can you. This is a call to find the middle ground, to open up your mind to new possibilities, and to make real progress by working with each other rather than against each other.

------

Michael Wood III is co-founder of Energy Terminal, a platform that aims to build the next generation of energy leaders and to bridge the gap between youth and the energy industry.

This article originally ran on EnergyCapital.

Rice researchers score $45M from NIH for cancer-fighting tech

freshly funded

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

View All Listings